Eigenmann F, Bürgi H
Schweiz Med Wochenschr. 1978 Nov 25;108(47):1850-3.
Lithium acetate treatment of 6 patients with hyperthyroid Graves' disease and 6 patients with toxic nodular goiter is reported. Lithium acetate was administered either as monotherapy (group A) or combined with 45 mg carbimazole or methimazole (group B). A control group of 8 patients received methimazole or carbimazole only (group C). Lithium either alone or combined with thionamide drugs consistently lowered serum thyroxine and triiodothyronine with marked clinical improvement. After 7 days of treatment thyroxine was reduced by 28% (group A), 43% (group B) and 36% (group C). The respective decrease in triiodothyronine was 42%, 50% and 46%. The differences between three groups were not statistically significant. We conclude that lithium is a useful antithyroid agent for selected patients, since it is safe and effective even in severe cases, does not interfere with radioiodine uptake for diagnostic or therapeutic purposes and provides an alternative for patients allergic to thionamides.
本文报道了用醋酸锂治疗6例甲状腺功能亢进型格雷夫斯病患者和6例毒性结节性甲状腺肿患者的情况。醋酸锂的给药方式分为单一疗法（A组）或与45毫克卡比马唑或甲巯咪唑联合使用（B组）。8例患者组成的对照组仅接受甲巯咪唑或卡比马唑治疗（C组）。单独使用锂或与硫酰胺类药物联合使用均能持续降低血清甲状腺素和三碘甲状腺原氨酸水平，并伴有明显的临床改善。治疗7天后，甲状腺素水平在A组降低了28%，B组降低了43%，C组降低了36%。三碘甲状腺原氨酸的相应降幅分别为42%、50%和46%。三组之间的差异无统计学意义。我们得出结论，锂对特定患者是一种有用的抗甲状腺药物，因为它即使在严重病例中也是安全有效的，不影响用于诊断或治疗目的的放射性碘摄取，并且为对硫酰胺类过敏的患者提供了一种替代药物。
